

1 **Controlled Substances Amendments**

2025 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Kirk A. Cullimore

House Sponsor:

3 **LONG TITLE**

4 **General Description:**

5 This bill amends provisions related to certain controlled substances.

6 **Highlighted Provisions:**

7 This bill:

- 8 ▶ amends provisions related to providing psilocybin and methylenedioxymethamphetamine;
- 9 ▶ provides for the automatic rescheduling a certain type of psilocybin if rescheduled by the
- 10 federal government; and
- 11 ▶ extends a repeal date.

12 **Money Appropriated in this Bill:**

13 None

14 **Other Special Clauses:**

15 None

16 **Utah Code Sections Affected:**

17 AMENDS:

18 **58-37-3.5**, as enacted by Laws of Utah 2024, Chapter 539

19 **58-37-4**, as last amended by Laws of Utah 2024, Chapter 298

20 **63I-1-258**, as last amended by Laws of Utah 2024, Third Special Session, Chapter 5

22 *Be it enacted by the Legislature of the state of Utah:*

23 Section 1. Section **58-37-3.5** is amended to read:

24 **58-37-3.5 . Drugs for behavioral health treatment.**

25 (1) As used in this section:

26 (a) "Drug" means any form of psilocybin or methylenedioxymethamphetamine that is in
 27 federal Food and Drug Administration Phase 3 testing for an investigational drug
 28 described in 21 C.F.R. Part 312, or a natural or otherwise digestible state.

29 (b) "Health care [system] provider" means:

30 (i) a privately-owned, non-profit, vertically-integrated health care system that

- 31 operates at least 15 licensed hospitals in the state; [or]
- 32 (ii) a health care system closely affiliated with an institution of higher education
- 33 described in Section 53B-2-101[-] ;
- 34 (iii) a palliative care provider licensed under this title who has been living in the state
- 35 for at least five years; or
- 36 (iv) a licensed psychiatrist who has been licensed under this title for at least five
- 37 years and living in the state for at least five years.
- 38 (2) A health_care [system] provider may develop a behavioral health treatment program that
- 39 includes a treatment based on a drug that the health_care [system] provider determines is
- 40 supported by a broad collection of scientific and medical research.
- 41 (3) A health_care [system] provider described in Subsection (2):
- 42 (a) shall ensure that a drug used under the exclusive authority of this section is used by a
- 43 patient only under the [~~direct~~] indirect supervision and control of the [~~healthcare~~
- 44 ~~system and the healthcare system's health care providers who are licensed under this~~
- 45 ~~title~~] health care provider; and
- 46 (b) may not provide treatments that are authorized exclusively under this section to an
- 47 individual who is not at least 18 years old.
- 48 (4) Before July 1, [2026] 2027, a health_care [system] provider that creates a behavioral
- 49 health treatment program under this section shall provide a written report to the Health
- 50 and Human Services Interim Committee regarding:
- 51 (a) drugs used;
- 52 (b) health outcomes of patients;
- 53 (c) side effects of any drugs used; and
- 54 (d) any other information necessary for the Legislature to evaluate the medicinal value
- 55 of any drugs.
- 56 (5) An individual or entity that complies with this section when using, distributing,
- 57 possessing, administering, or supervising the use of, a drug is not guilty of a violation of
- 58 this title.

59 Section 2. Section **58-37-4** is amended to read:

60 **58-37-4 . Schedules of controlled substances -- Schedules I through V -- Findings**

61 **required -- Specific substances included in schedules.**

- 62 (1) There are established five schedules of controlled substances known as Schedules I, II,
- 63 III, IV, and V which consist of substances listed in this section.
- 64 (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the

- 65 official name, common or usual name, chemical name, or brand name designated:
- 66 (a) Schedule I:
- 67 (i) Unless specifically excepted or unless listed in another schedule, any of the
- 68 following opiates, including their isomers, esters, ethers, salts, and salts of
- 69 isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
- 70 salts is possible within the specific chemical designation:
- 71 (A) Acetyl-alpha-methylfentanyl
- 72 (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
- 73 (B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
- 74 (C) Acetylmethadol;
- 75 (D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);
- 76 (E) Allylprodine;
- 77 (F) Alphacetylmethadol, except levo-alphacetylmethadol also known as
- 78 levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
- 79 (G) Alphameprodine;
- 80 (H) Alphamethadol;
- 81 (I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
- 82 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
- 83 (J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
- 84 piperidinyl]-N-phenylpropanamide);
- 85 (K) Benzylpiperazine;
- 86 (L) Benzethidine;
- 87 (M) Betacetylmethadol;
- 88 (N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
- 89 piperidinyl]-N-phenylpropanamide);
- 90 (O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
- 91 phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
- 92 (P) Betameprodine;
- 93 (Q) Betamethadol;
- 94 (R) Betaprodine;
- 95 (S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);
- 96 (T) Clonitazene;
- 97 (U) Cyclopropyl fentanyl
- 98 (N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

- 99 (V) Dextromoramide;
- 100 (W) Diampromide;
- 101 (X) Diethylthiambutene;
- 102 (Y) Difenoxin;
- 103 (Z) Dimenoxadol;
- 104 (AA) Dimepheptanol;
- 105 (BB) Dimethylthiambutene;
- 106 (CC) Dioxaphetyl butyrate;
- 107 (DD) Dipipanone;
- 108 (EE) Ethylmethylthiambutene;
- 109 (FF) Etizolam
(1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);
- 110 (GG) Etonitazene;
- 111 (HH) Etoxeridine;
- 112 (II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
113 furan-2-carboxamide);
- 114 (JJ) Furethidine;
- 115 (KK) Hydroxypethidine;
- 116 (LL) Ketobemidone;
- 117 (MM) Levomoramide;
- 118 (NN) Levophenacilmorphan;
- 119 (OO) Methoxyacetyl fentanyl
120 (2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide);
- 121 (PP) Morpheridine;
- 122 (QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 123 (RR) Noracymethadol;
- 124 (SS) Norlevorphanol;
- 125 (TT) Normethadone;
- 126 (UU) Norpipanone;
- 127 (VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
128 propanamide);
- 129 (WW) Para-fluoroisobutyryl fentanyl
130 (N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
- 131 (XX) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 132

- 133 (YY) Phenadoxone;
134 (ZZ) Phenampromide;
135 (AAA) Phenomorphan;
136 (BBB) Phenoperidine;
137 (CCC) Piritramide;
138 (DDD) Proheptazine;
139 (EEE) Properidine;
140 (FFF) Propiram;
141 (GGG) Racemoramide;
142 (HHH) Tetrahydrofuran fentanyl
143 (N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
144 (III) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide);
145 (JJJ) Tilidine;
146 (KKK) Trimeperidine;
147 (LLL) 3-methylfentanyl, including the optical and geometric isomers
148 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide);
149 (MMM) 3-methylthiofentanyl
150 (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
151 (NNN) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also
152 known as U-47700; and
153 (OOO) 4-cyano CUMYL-BUTINACA.
- (ii) Unless specifically excepted or unless listed in another schedule, any of the
154 following opium derivatives, their salts, isomers, and salts of isomers when the
155 existence of the salts, isomers, and salts of isomers is possible within the specific
156 chemical designation:
157
158 (A) Acetorphine;
159 (B) Acetyldihydrocodeine;
160 (C) Benzylmorphine;
161 (D) Codeine methylbromide;
162 (E) Codeine-N-Oxide;
163 (F) Cyprenorphine;
164 (G) Desomorphine;
165 (H) Dihydromorphine;
166 (I) Drotebanol;

- 167 (J) Etorphine (except hydrochloride salt);
168 (K) Heroin;
169 (L) Hydromorphenol;
170 (M) Methyldesorphine;
171 (N) Methylhydromorphone;
172 (O) Morphine methylbromide;
173 (P) Morphine methylsulfonate;
174 (Q) Morphine-N-Oxide;
175 (R) Myrophine;
176 (S) Nicocodeine;
177 (T) Nicomorphine;
178 (U) Normorphine;
179 (V) Pholcodine; and
180 (W) Thebacon.
- 181 (iii) Unless specifically excepted or unless listed in another schedule, any material,
182 compound, mixture, or preparation which contains any quantity of the following
183 hallucinogenic substances, or which contains any of their salts, isomers, and salts
184 of isomers when the existence of the salts, isomers, and salts of isomers is possible
185 within the specific chemical designation; as used in this Subsection (2)(a)(iii)
186 only, "isomer" includes the optical, position, and geometric isomers:
- 187 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; α
188 -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;
189 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
190 4-bromo-2,5-dimethoxy- α -methylphenethylamine; 4-bromo-2,5-DMA;
191 (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names:
192 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB;
193 2C-B, Nexus;
194 (D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy- α
195 -methylphenethylamine; 2,5-DMA;
196 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
197 (F) 4-methoxyamphetamine, some trade or other names: 4-methoxy- α
198 -methylphenethylamine; paramethoxyamphetamine, PMA;
199 (G) 5-methoxy-3,4-methylenedioxyamphetamine;
200 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:

- 201 4-methyl-2,5-dimethoxy- α -methylphenethylamine; "DOM"; and "STP";
- 202 (I) 3,4-methylenedioxy amphetamine;
- 203 (J) 3,4-methylenedioxymethamphetamine (MDMA);
- 204 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
- 205 alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE,
- 206 MDEA;
- 207 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
- 208 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy
- 209 MDA;
- 210 (M) 3,4,5-trimethoxy amphetamine;
- 211 (N) Bufotenine, some trade and other names: 3-(β
- 212 -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol;
- 213 N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
- 214 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
- 215 (P) Dimethyltryptamine, some trade or other names: DMT;
- 216 (Q) Ibogaine, some trade and other names: 7-Ethyl-6,6 β
- 217 ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2]
- 218 azepino [5,4-b] indole; Tabernanthe iboga;
- 219 (R) Lysergic acid diethylamide;
- 220 (S) Marijuana;
- 221 (T) Mescaline;
- 222 (U) Parahexyl, some trade or other names:
- 223 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;
- 224 Synhexyl;
- 225 (V) Peyote, meaning all parts of the plant presently classified botanically as
- 226 Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any
- 227 extract from any part of such plant, and every compound, manufacture, salts,
- 228 derivative, mixture, or preparation of such plant, its seeds or extracts
- 229 (Interprets 21 USC 812(c), Schedule I(c) (12));
- 230 (W) N-ethyl-3-piperidyl benzilate;
- 231 (X) N-methyl-3-piperidyl benzilate;
- 232 (Y) Psilocybin, except as provided in Subsection (3);
- 233 (Z) Psilocyn;
- 234 (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis

- 235 (cannabis plant), except for marijuana as defined in Subsection 58-37-2
236 (1)(aa)(i)(E), as well as synthetic equivalents of the substances contained in the
237 cannabis plant, or in the resinous extractives of Cannabis, sp. and/or synthetic
238 substances, derivatives, and their isomers with similar chemical structure and
239 pharmacological activity to those substances contained in the plant, such as the
240 following: $\Delta 1$ cis or trans tetrahydrocannabinol, and their optical isomers $\Delta 6$ cis or
241 trans tetrahydrocannabinol, and their optical isomers $\Delta 3,4$ cis or trans
242 tetrahydrocannabinol, and its optical isomers, and since nomenclature of these
243 substances is not internationally standardized, compounds of these structures,
244 regardless of numerical designation of atomic positions covered;
- 245 (BB) Ethylamine analog of phencyclidine, some trade or other names:
246 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
247 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
- 248 (CC) Pyrrolidine analog of phencyclidine, some trade or other names:
249 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
- 250 (DD) Thiophene analog of phencyclidine, some trade or other names:
251 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine,
252 TPCP, TCP; and
- 253 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
- 254 (iv) Unless specifically excepted or unless listed in another schedule, any material
255 compound, mixture, or preparation which contains any quantity of the following
256 substances having a depressant effect on the central nervous system, including its
257 salts, isomers, and salts of isomers when the existence of the salts, isomers, and
258 salts of isomers is possible within the specific chemical designation:
- 259 (A) Mecloqualone; and
260 (B) Methaqualone.
- 261 (v) Any material, compound, mixture, or preparation containing any quantity of the
262 following substances having a stimulant effect on the central nervous system,
263 including their salts, isomers, and salts of isomers:
- 264 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline;
265 or 4,5-dihydro-5-phenyl-2-oxazolamine;
- 266 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
267 alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
- 268 (C) Fenethylamine;

- 269 (D) Methcathinone, some other names: 2-(methylamino)-propiofenone;
 270 alpha-(methylamino)propiofenone; 2-(methylamino)-1-phenylpropan-1-one;
 271 alpha-N-methylaminopropiofenone; monomethylpropion; ephedrone;
 272 N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432,
 273 its salts, optical isomers, and salts of optical isomers;
- 274 (E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
- 275 (F) N-ethylamphetamine; and
- 276 (G) N,N-dimethylamphetamine, also known as
 277 N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine.
- 278 (vi) Any material, compound, mixture, or preparation which contains any quantity of
 279 the following substances, including their optical isomers, salts, and salts of
 280 isomers, subject to temporary emergency scheduling:
- 281 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
 282 (B) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
- 283 (vii) Unless specifically excepted or unless listed in another schedule, any material,
 284 compound, mixture, or preparation which contains any quantity of gamma
 285 hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and
 286 salts of isomers.
- 287 (b) Schedule II:
- 288 (i) Unless specifically excepted or unless listed in another schedule, any of the
 289 following substances whether produced directly or indirectly by extraction from
 290 substances of vegetable origin, or independently by means of chemical synthesis,
 291 or by a combination of extraction and chemical synthesis:
- 292 (A) Opium and opiate, and any salt, compound, derivative, or preparation of
 293 opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene,
 294 naloxone, and naltrexone, and their respective salts, but including:
- 295 (I) Raw opium;
 296 (II) Opium extracts;
 297 (III) Opium fluid;
 298 (IV) Powdered opium;
 299 (V) Granulated opium;
 300 (VI) Tincture of opium;
 301 (VII) Codeine;
 302 (VIII) Ethylmorphine;

- 303 (IX) Etorphine hydrochloride;
- 304 (X) Hydrocodone;
- 305 (XI) Hydromorphone;
- 306 (XII) Metopon;
- 307 (XIII) Morphine;
- 308 (XIV) Oxycodone;
- 309 (XV) Oxymorphone; and
- 310 (XVI) Thebaine;
- 311 (B) Any salt, compound, derivative, or preparation which is chemically equivalent
- 312 or identical with any of the substances referred to in Subsection (2)(b)(i)(A),
- 313 except that these substances may not include the isoquinoline alkaloids of
- 314 opium;
- 315 (C) Opium poppy and poppy straw;
- 316 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves,
- 317 and any salt, compound, derivative, or preparation which is chemically
- 318 equivalent or identical with any of these substances, and includes cocaine and
- 319 ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives,
- 320 whether derived from the coca plant or synthetically produced, except the
- 321 substances may not include decocainized coca leaves or extraction of coca
- 322 leaves, which extractions do not contain cocaine or ecgonine; and
- 323 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in
- 324 either liquid, solid, or powder form which contains the phenanthrene alkaloids
- 325 of the opium poppy.
- 326 (ii) Unless specifically excepted or unless listed in another schedule, any of the
- 327 following opiates, including their isomers, esters, ethers, salts, and salts of
- 328 isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and
- 329 salts is possible within the specific chemical designation, except dextrorphan and
- 330 levopropoxyphene:
- 331 (A) Alfentanil;
- 332 (B) Alphaprodine;
- 333 (C) Anileridine;
- 334 (D) Bezitramide;
- 335 (E) Bulk dextropropoxyphene (nondosage forms);
- 336 (F) Carfentanil;

- 337 (G) Dihydrocodeine;
- 338 (H) Diphenoxylate;
- 339 (I) Fentanyl;
- 340 (J) Isomethadone;
- 341 (K) Levo-alpha-acetylmethadol, some other names: levo-alpha-acetylmethadol,
- 342 levomethadyl acetate, or LAAM;
- 343 (L) Levomethorphan;
- 344 (M) Levorphanol;
- 345 (N) Metazocine;
- 346 (O) Methadone;
- 347 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
- 348 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1,
- 349 1-diphenylpropane-carboxylic acid;
- 350 (R) Pethidine (meperidine);
- 351 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 352 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 353 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 354 (V) Phenazocine;
- 355 (W) Piminodine;
- 356 (X) Racemethorphan;
- 357 (Y) Racemorphan;
- 358 (Z) Remifentanyl; and
- 359 (AA) Sufentanyl.
- 360 (iii) Unless specifically excepted or unless listed in another schedule, any material,
- 361 compound, mixture, or preparation which contains any quantity of the following
- 362 substances having a stimulant effect on the central nervous system:
- 363 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 364 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
- 365 (C) Phenmetrazine and its salts; and
- 366 (D) Methylphenidate.
- 367 (iv) Unless specifically excepted or unless listed in another schedule, any material,
- 368 compound, mixture, or preparation which contains any quantity of the following
- 369 substances having a depressant effect on the central nervous system, including its
- 370 salts, isomers, and salts of isomers when the existence of the salts, isomers, and

- 371 salts of isomers is possible within the specific chemical designation:
- 372 (A) Amobarbital;
- 373 (B) Glutethimide;
- 374 (C) Pentobarbital;
- 375 (D) Phencyclidine;
- 376 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
- 377 1-piperidinocyclohexanecarbonitrile (PCC); and
- 378 (F) Secobarbital.
- 379 (v)(A) Unless specifically excepted or unless listed in another schedule, any
- 380 material, compound, mixture, or preparation which contains any quantity of
- 381 Phenylacetone.
- 382 (B) Some of these substances may be known by trade or other names:
- 383 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
- 384 (vi) Nabilone, another name for nabilone: (\pm)
- 385 *-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,*
- 386 *6-dimethyl-9H-dibenzo[b,d]pyran-9-one.*
- 387 (vii) A drug product or preparation that contains any component of marijuana,
- 388 including tetrahydrocannabinol, and is approved by the United States Food and
- 389 Drug Administration and scheduled by the Drug Enforcement Administration in
- 390 Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 391 (c) Schedule III:
- 392 (i) Unless specifically excepted or unless listed in another schedule, any material,
- 393 compound, mixture, or preparation which contains any quantity of the following
- 394 substances having a stimulant effect on the central nervous system, including its
- 395 salts, isomers whether optical, position, or geometric, and salts of the isomers
- 396 when the existence of the salts, isomers, and salts of isomers is possible within the
- 397 specific chemical designation:
- 398 (A) Those compounds, mixtures, or preparations in dosage unit form containing
- 399 any stimulant substances listed in Schedule II, which compounds, mixtures, or
- 400 preparations were listed on August 25, 1971, as excepted compounds under
- 401 Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other
- 402 drug of the quantitative composition shown in that list for those drugs or which
- 403 is the same except that it contains a lesser quantity of controlled substances;
- 404 (B) Benzphetamine;

- 405 (C) Chlorphentermine;
- 406 (D) Clortermine; and
- 407 (E) Phendimetrazine.
- 408 (ii) Unless specifically excepted or unless listed in another schedule, any material,
- 409 compound, mixture, or preparation which contains any quantity of the following
- 410 substances having a depressant effect on the central nervous system:
- 411 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
- 412 pentobarbital, or any salt of any of them, and one or more other active
- 413 medicinal ingredients which are not listed in any schedule;
- 414 (B) Any suppository dosage form containing amobarbital, secobarbital, or
- 415 pentobarbital, or any salt of any of these drugs which is approved by the United
- 416 States Food and Drug Administration for marketing only as a suppository;
- 417 (C) Any substance which contains any quantity of a derivative of barbituric acid
- 418 or any salt of any of them;
- 419 (D) Chlorhexadol;
- 420 (E) Buprenorphine;
- 421 (F) Any drug product containing gamma hydroxybutyric acid, including its salts,
- 422 isomers, and salts of isomers, for which an application is approved under the
- 423 federal Food, Drug, and Cosmetic Act, Section 505;
- 424 (G) Ketamine, its salts, isomers, and salts of isomers, some other names for
- 425 ketamine: \pm -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
- 426 (H) Lysergic acid;
- 427 (I) Lysergic acid amide;
- 428 (J) Methyprylon;
- 429 (K) Sulfondiethylmethane;
- 430 (L) Sulfonethylmethane;
- 431 (M) Sulfonmethane; and
- 432 (N) Tiletamine and zolazepam or any of their salts, some trade or other names for
- 433 a tiletamine-zolazepam combination product: Telazol, some trade or other
- 434 names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade
- 435 or other names for zolazepam:
- 436 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e]
- 437 [1,4]-diazepin-7(1H)-one, flupyrazapon.
- 438 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in

- 439 a U.S. Food and Drug Administration approved drug product, some other names
440 for dronabinol:
441 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol,
442 or (-)-delta-9-(trans)-tetrahydrocannabinol.
- 443 (iv) Nalorphine.
- 444 (v) Unless specifically excepted or unless listed in another schedule, any material,
445 compound, mixture, or preparation containing limited quantities of any of the
446 following narcotic drugs, or their salts calculated as the free anhydrous base or
447 alkaloid:
- 448 (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
449 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline
450 alkaloid of opium;
- 451 (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
452 milligrams per dosage unit, with one or more active non-narcotic ingredients in
453 recognized therapeutic amounts;
- 454 (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
455 more than 15 milligrams per dosage unit, with a fourfold or greater quantity of
456 an isoquinoline alkaloid of opium;
- 457 (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not
458 more than 15 milligrams per dosage unit, with one or more active, non-narcotic
459 ingredients in recognized therapeutic amounts;
- 460 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more
461 than 90 milligrams per dosage unit, with one or more active non-narcotic
462 ingredients in recognized therapeutic amounts;
- 463 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
464 than 15 milligrams per dosage unit, with one or more active, non-narcotic
465 ingredients in recognized therapeutic amounts;
- 466 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams,
467 or not more than 25 milligrams per dosage unit, with one or more active,
468 non-narcotic ingredients in recognized therapeutic amounts; and
- 469 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams
470 with one or more active, non-narcotic ingredients in recognized therapeutic
471 amounts.
- 472 (vi) Unless specifically excepted or unless listed in another schedule, anabolic

- 473 steroids including any of the following or any isomer, ester, salt, or derivative of
474 the following that promotes muscle growth:
- 475 (A) Boldenone;
 - 476 (B) Chlorotestosterone (4-chlortestosterone);
 - 477 (C) Clostebol;
 - 478 (D) Dehydrochlormethyltestosterone;
 - 479 (E) Dihydrotestosterone (4-dihydrotestosterone);
 - 480 (F) Drostanolone;
 - 481 (G) Ethylestrenol;
 - 482 (H) Fluoxymesterone;
 - 483 (I) Formebolone (formebolone);
 - 484 (J) Mesterolone;
 - 485 (K) Methandienone;
 - 486 (L) Methandranone;
 - 487 (M) Methandriol;
 - 488 (N) Methandrostenolone;
 - 489 (O) Methenolone;
 - 490 (P) Methyltestosterone;
 - 491 (Q) Mibolerone;
 - 492 (R) Nandrolone;
 - 493 (S) Norethandrolone;
 - 494 (T) Oxandrolone;
 - 495 (U) Oxymesterone;
 - 496 (V) Oxymetholone;
 - 497 (W) Stanolone;
 - 498 (X) Stanozolol;
 - 499 (Y) Testolactone;
 - 500 (Z) Testosterone; and
 - 501 (AA) Trenbolone.
- 502 (vii) Anabolic steroids expressly intended for administration through implants to
503 cattle or other nonhuman species, and approved by the Secretary of Health and
504 Human Services for use, may not be classified as a controlled substance.
- 505 (viii) A drug product or preparation that contains any component of marijuana,
506 including tetrahydrocannabinol, and is approved by the United States Food and

507 Drug Administration and scheduled by the Drug Enforcement Administration in
508 Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513.

509 (ix) Nabiximols.

510 (d) Schedule IV:

511 (i) Unless specifically excepted or unless listed in another schedule, any material,
512 compound, mixture, or preparation containing not more than 1 milligram of
513 difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or
514 any salts of any of them.

515 (ii) Unless specifically excepted or unless listed in another schedule, any material,
516 compound, mixture, or preparation which contains any quantity of the following
517 substances, including its salts, isomers, and salts of isomers when the existence of
518 the salts, isomers, and salts of isomers is possible within the specific chemical
519 designation:

520 (A) Alprazolam;

521 (B) Barbital;

522 (C) Bromazepam;

523 (D) Butorphanol;

524 (E) Camazepam;

525 (F) Carisoprodol;

526 (G) Chloral betaine;

527 (H) Chloral hydrate;

528 (I) Chlordiazepoxide;

529 (J) Clobazam;

530 (K) Clonazepam;

531 (L) Clorazepate;

532 (M) Clotiazepam;

533 (N) Cloxazolam;

534 (O) Delorazepam;

535 (P) Diazepam;

536 (Q) Dichloralphenazone;

537 (R) Estazolam;

538 (S) Ethchlorvynol;

539 (T) Ethinamate;

540 (U) Ethyl loflazepate;

- 541 (V) Fludiazepam;
542 (W) Flunitrazepam;
543 (X) Flurazepam;
544 (Y) Halazepam;
545 (Z) Haloxazolam;
546 (AA) Ketazolam;
547 (BB) Loprazolam;
548 (CC) Lorazepam;
549 (DD) Lormetazepam;
550 (EE) Mebutamate;
551 (FF) Medazepam;
552 (GG) Meprobamate;
553 (HH) Methohexital;
554 (II) Methylphenobarbital (mephobarbital);
555 (JJ) Midazolam;
556 (KK) Nimetazepam;
557 (LL) Nitrazepam;
558 (MM) Nordiazepam;
559 (NN) Oxazepam;
560 (OO) Oxazolam;
561 (PP) Paraldehyde;
562 (QQ) Pentazocine;
563 (RR) Petrichloral;
564 (SS) Phenobarbital;
565 (TT) Pinazepam;
566 (UU) Prazepam;
567 (VV) Quazepam;
568 (WW) Temazepam;
569 (XX) Tetrazepam;
570 (YY) Tramadol;
571 (ZZ) Triazolam;
572 (AAA) Zaleplon; and
573 (BBB) Zolpidem.
574 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains

575 any quantity of the following substances, including its salts, isomers whether
576 optical, position, or geometric, and salts of the isomers when the existence of the
577 salts, isomers, and salts of isomers is possible.

578 (iv) Unless specifically excepted or unless listed in another schedule, any material,
579 compound, mixture, or preparation which contains any quantity of the following
580 substances having a stimulant effect on the central nervous system, including its
581 salts, isomers whether optical, position, or geometric isomers, and salts of the
582 isomers when the existence of the salts, isomers, and salts of isomers is possible
583 within the specific chemical designation:

584 (A) Cathine ((+)-norpseudoephedrine);

585 (B) Diethylpropion;

586 (C) Fencamfamine;

587 (D) Fenproporex;

588 (E) Mazindol;

589 (F) Mefenorex;

590 (G) Modafinil;

591 (H) Pemoline, including organometallic complexes and chelates thereof;

592 (I) Phentermine;

593 (J) Pipradrol;

594 (K) Sibutramine; and

595 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

596 (v) Unless specifically excepted or unless listed in another schedule, any material,
597 compound, mixture, or preparation which contains any quantity of
598 dextropropoxyphene (alpha-(+)-4-dimethylamino-1,
599 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.

600 (vi) A drug product or preparation that contains any component of marijuana and is
601 approved by the United States Food and Drug Administration and scheduled by
602 the Drug Enforcement Administration in Schedule IV of the federal Controlled
603 Substances Act, Title II, P.L. 91-513.

604 (e) Schedule V:

605 (i) Any compound, mixture, or preparation containing any of the following limited
606 quantities of narcotic drugs, or their salts calculated as the free anhydrous base or
607 alkaloid, which includes one or more non-narcotic active medicinal ingredients in
608 sufficient proportion to confer upon the compound, mixture, or preparation

- 609 valuable medicinal qualities other than those possessed by the narcotic drug alone:
- 610 (A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
- 611 (B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
- 612 grams;
- 613 (C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
- 614 grams;
- 615 (D) not more than 2.5 milligrams of diphenoxylate and not less than 25
- 616 micrograms of atropine sulfate per dosage unit;
- 617 (E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
- 618 (F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of
- 619 atropine sulfate per dosage unit; and
- 620 (G) unless specifically exempted or excluded or unless listed in another schedule,
- 621 any material, compound, mixture, or preparation which contains Pyrovalerone
- 622 having a stimulant effect on the central nervous system, including its salts,
- 623 isomers, and salts of isomers.
- 624 (ii) A drug product or preparation that contains any component of marijuana,
- 625 including cannabidiol, and is approved by the United States Food and Drug
- 626 Administration and scheduled by the Drug Enforcement Administration in
- 627 Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 628 (iii) Gabapentin.

629 (3) If the federal government schedules the pharmaceutical composition of crystalline

630 polymorph psilocybin in a schedule that is not schedule I, that composition is deemed

631 scheduled under this section in the same schedule that the composition is scheduled

632 under 21 U.S.C. Sec. 812 and 21 C.F.R. Sec. 1308.14.

633 Section 3. Section **63I-1-258** is amended to read:

634 **63I-1-258 . Repeal dates: Title 58.**

- 635 (1) Title 58, Chapter 13, Health Care Providers Immunity from Liability Act, is repealed
- 636 July 1, 2026.
- 637 (2) Title 58, Chapter 15, Health Facility Administrator Act, is repealed July 1, 2025.
- 638 (3) Title 58, Chapter 20b, Environmental Health Scientist Act, is repealed July 1, 2028.
- 639 (4) Section 58-37-3.5, Drugs for behavioral health treatment, is repealed July 1, [2027] 2029.
- 640 (5) Subsection 58-37-6(7)(f)(iii), regarding a seven-day opiate supply restriction, is
- 641 repealed July 1, 2032.
- 642 (6) Title 58, Chapter 40, Recreational Therapy Practice Act, is repealed July 1, 2033.

- 643 (7) Title 58, Chapter 41, Speech-Language Pathology and Audiology Licensing Act, is
644 repealed July 1, 2029.
- 645 (8) Title 58, Chapter 46a, Hearing Instrument Specialist Licensing Act, is repealed July 1,
646 2033.
- 647 (9) Title 58, Chapter 47b, Massage Therapy Practice Act, is repealed July 1, 2034.
- 648 (10) Subsection 58-55-201(2), regarding the Alarm System and Security Licensing
649 Advisory Board, is repealed July 1, 2027.
- 650 (11) Title 58, Chapter 61, Part 7, Behavior Analyst Licensing Act, is repealed July 1, 2026.
- 651 Section 4. **Effective Date.**
- 652 This bill takes effect on May 7, 2025.